WIC
BCRX icon

Woodmont Investment Counsel’s BioCryst Pharmaceuticals BCRX Stock Holding History

Woodmont Investment Counsel’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2,115
Closed -$9K – 230
2016
Q3 		$9K Buy
+2,115
New +$8.45K ﹤0.01% 477
2016
Q2 		– Sell
-2,115
Closed -$6K – 209
2016
Q1 		$6K Hold
2,115
– – ﹤0.01% 447
2015
Q4 		$22K Hold
2,115
– – 0.01% 347
2015
Q3 		$24K Hold
2,115
– – 0.01% 326
2015
Q2 		$32K Buy
+2,115
New +$24K 0.01% 309

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Woodmont Investment Counsel's BCRX Position: Q4 2016 in Review

Woodmont Investment Counsel sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2016, closing a stake of 2,115 shares — an estimated $9K sold.

Woodmont Investment Counsel first reported a position in BCRX in Q2 2015 and held it in 5 quarters. The position peaked at $32K in Q2 2015. 112 funds tracked by Wall St. Rank hold BCRX as of Q4 2016.

  • Woodmont Investment Counsel reported no remaining BioCryst Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Woodmont Investment Counsel sold 2,115 BioCryst Pharmaceuticals shares in Q4 2016, an estimated $9K.
  • Woodmont Investment Counsel first reported a position in BioCryst Pharmaceuticals in Q2 2015 and held it in 5 quarters.
  • Woodmont Investment Counsel's BioCryst Pharmaceuticals position peaked at $32K in Q2 2015.
  • 112 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2016.

Based on Woodmont Investment Counsel's 13F filing for Q4 2016, filed 13 Feb 2017.